TESAMORELIN (10mg)

Tesamorelin 10mg, an FDA-approved GHRH analogue for GH axis research. (99%) Purity verified here on Australian soil at The University of Melbourne.

Tesamorelin is a growth hormone releasing hormone analogue consisting of human GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus. Developed by Theratechnologies, it was FDA-approved in 2010 under the brand name Egrifta, making it one of the few GHRH peptides with regulatory approval.

Unlike Sermorelin which contains only the first 29 amino acids, Tesamorelin includes the full 44-amino acid GHRH sequence. The trans-3-hexenoic acid modification at the N-terminus provides enhanced stability against enzymatic degradation while maintaining full GHRH receptor binding activity.

Research has examined Tesamorelin’s effects on GH secretion, body composition, and metabolic parameters. Clinical studies have documented its pharmacokinetics, dose-response relationships, and long-term effects in various research contexts, providing extensive characterisation data.

The peptide’s regulatory approval status means it has undergone rigorous safety and efficacy evaluation, and substantial published literature exists documenting its biological effects. This makes it particularly valuable for research requiring a well-characterised GHRH analogue with established safety data.

Gen Ex Peptides supplies Tesamorelin tested at an Australian university laboratory not generic overseas certificates. Each batch is verified for purity (99%) using HPLC and mass spectrometry.